Back to search results

Using Urine Samples to Identify Lung Cancer

This study is looking into a new way to detect non-small cell lung cancer (NSCLC) using urine samples. Researchers are testing an animal biosensor platform (ABP) that uses trained animals to smell specific chemicals in urine. These chemicals are thought to be unique to people with lung cancer. The goal is to see if this method can accurately identify NSCLC without needing invasive procedures like biopsies. You may be able to join if you are between 18 and 90 years old and have been diagnosed with NSCLC, are suspected of having NSCLC, or do not have NSCLC. This study aims to find out if the ABP can detect these NSCLC-specific chemicals in urine within two years.

Study design
This is an observational study planning to enroll 210 participants. It does not specify a phase.
What's involved
You would provide a urine sample. The trial record does not specify other visits, procedures, or tests.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint for detecting NSCLC-specific chemicals is measured at 2 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06033248

Using Urine Samples to Identify Lung Cancer

Recruiting
Not specifiedAges 18–90Observational
Memorial Sloan Kettering Cancer Center
~210 participants
Updated 2026-07-21 on ClinicalTrials.gov
What's tested:urine sample

At a glance

Recruiting sites
7 of 7 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
detect the presence or absence of NSCLC-specific VOCs
Measured over 2 years

Conditions

Non Small Cell Lung Cancer

Explore related trials

Lung Non-Small Cell Carcinoma

Where it's being run

7 sites across 2 states
New York4
New Jersey3

Study leadership

  • Gaetano Rocco, MD · PRINCIPAL_INVESTIGATOR · Memorial Sloan Kettering Cancer Center

Who to contact

Gaetano Rocco, MD
[email protected]
212-639-3478
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Phase I (with NSCLC): Aged 18 to 90 years with histologically proven, previously untreated stage I, II, or IIIA NSCLC
Phase I (without NSCLC): Aged 18 to 90 years with patient confirmed absence of NSCLC
Phase II: Aged 18 to 90 years with suspected but undiagnosed stage I, II, or IIIA NSCLC by CT and/or PET scan criteria

Exclusion

Aged \<18 years
Lack of available results from low-dose CT
Receipt of radiation, chemotherapy, biological therapy, resection, or any other treatment for any cancer in the previous year
Pregnant (for women)
Taking drugs that affect the immune system
Chronic disease related to the immune system
Missing clinical data (i.e., current clinical staging)

What this trial measures

  • detect the presence or absence of NSCLC-specific VOCs2 years

    in urine samples